Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
申请人:Genzyme Corporation
公开号:US20030050299A1
公开(公告)日:2003-03-13
Disclosed is a novel enantiomeric synthesis cermamide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
[EN] IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION D'ÉLIGLUSTAT
申请人:REDDYS LAB LTD DR
公开号:WO2015059679A1
公开(公告)日:2015-04-30
The present invention provides an improved process for the preparation of eliglustat to salts thereof. Present invention also provides a crystalline eliglustat free base form R1.
SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS
申请人:GENZYME CORPORATION
公开号:US20150148534A1
公开(公告)日:2015-05-28
Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors
申请人:GENZYME CORPORATION
公开号:EP2067775A1
公开(公告)日:2009-06-10
Disclosed is a novel enantiomeric synthesis of ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
公开号:EP3851439A1
公开(公告)日:2021-07-21
The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.